Skip to main content
Fig. 1 | Biology Direct

Fig. 1

From: Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy

Fig. 1

High expression of BRAF indicates poor prognosis in AML and MDS patients. A Hierarchical clustering of differentially expressed genes in MDS and AML patients compared to healthy controls; B Relative expression level of BRAF was normalized to β-actin in healthy controls, MDS patients, AML patients and sAML patients; C Relative expression level of BRAF was normalized to β-actin in different stage of AML by RT-qPCR; D ROC curve analysis of BRAF expression for discriminating AML patients from controls; E Prognostic impact of BRAF expression on AML patients; F Prognostic impact of BRAF expression on AML patients in TCGA database; G Relative expression level of BRAF was normalized to β-actin in healthy controls, LR-MDS patients, IR-MDS patients, and HR-MDS patients; H Prognostic impact of BRAF expression on MDS patients, I Survival-Analysis of MDS patients with different BRAF experssion and IPSS group. *P < .05; **P < .01; ***P < .001; ****P < .001. Error bars indicate the SD

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us